About Cytochroma
Cytochroma is a Healthcare company based in Bannockburn (Australia) founded in 1996 by Kate Cameron, and was acquired by Opko Health in January 2013. Cytochroma has raised $74.03 million across 7 funding rounds from investors including Opko Health, BDC and Caisse de depot et placement du Quebec. The company was acqui-hired. Its focus areas include Life Sciences, Nephrology, Drugs and Metabolic Diseases.
Company details
Developer of therapeutics to treat secondary hyperparathyroidism (SHPT). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4, or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
- Headquarters Bannockburn, Australia
- Founders Kate Cameron
- Stage Acquired
- SectorsHealthcare
- Website cytochroma.com
- Social LinkedIn
- Acquired by Opko Health (Jan 2013)
- Total Equity Funding$74.03M (USD)
in 7 rounds
- Latest Funding Round$1M (USD), Series C
Jul 2011
- InvestorsOpko Health
& 9 more
- Acquired byOpko Health
(Jan 2013)
Funding Insights of Cytochroma
Cytochroma has successfully raised a total of $74.03M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $1 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.03M
- Total Rounds 7
- Last Round Series C — $1M
- First Round $7.61M
(Oct 2001)
- Investors Count 9
All 7 funding rounds of Cytochroma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2011 | $1M | Series C | – | – | |
| Jul 2008 | $43.98M | Series C | – | – | |
| Mar 2007 | $3M | Series C | – | – | – |
| May 2005 | $12.04M | Series C | – | – | |
| Dec 2002 | $4.17M | Series B | – | – | |
| Dec 2001 | $2.23M | Series B | – | – | – |
| Oct 2001 | $7.61M | Series B | – | – |
10 investors in total: 10 institutional.
Investors in Cytochroma
Cytochroma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Opko Health, BDC and Caisse de depot et placement du Quebec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage technology startups are supported through investments by MaRS IAF. | marsiaf.com | Canada | ||
Stage-agnostic sector-agnostic VC firm investing in Canada and the US | growthworks.ca | Vancouver, Canada | ||
Private equity buyouts are targeted by the investment firm. | vgpartners.com | Toronto, Canada | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investment strategies are provided across diverse asset classes and markets. | 1965 | cdpq.com | Quebec City, Canada | |
Tech & Energy focused investment management firm investing primarily in Canada | venturelinkfunds.com | Toronto, Canada | ||
| genechem.com | ||||
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada | |
Innovative therapies and drugs are developed by the pharmaceutical company. | 1678 | mt-pharma.co.jp | Osaka, Japan | |
Molecular diagnostic products for prostate cancer assessment are provided. | 1991 | opko.com | Miami, United States |
Investor details for Cytochroma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cytochroma
1 people are tracked at Cytochroma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kate Cameron | Founder | Leadership |
Complete people profiles for Cytochroma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cytochroma
4 dated milestones of Cytochroma across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Cytochroma is founded.
- Funding First funding round of $7.6M.
- Funding Latest funding round, Series C, of $1.0M.
- Exit Acquired by Opko Health.
Web traffic of Cytochroma
Websites that share an audience with Cytochroma (cytochroma.com).
Websites whose visitors overlap most with Cytochroma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nutraingredients.com | 100% | #269,209 | View details | ||
vitaminddeficiencysymptomsguide.com | vitaminddeficiencysymptomsguide.com | 78% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cytochroma
Cytochroma was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Cytochroma is headquartered in Bannockburn, Australia. It is registered at Bannockburn, Victoria, Australia.
Cytochroma is a funded company, having raised a total of $74.03M across 7 funding rounds to date. The company's 1st funding round was a Series B of $7.61M, raised on Oct 2001.
Developer of therapeutics to treat secondary hyperparathyroidism (SHPT). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4, or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Cytochroma has 10 investors. Key investors include Opko Health, BDC, Caisse de depot et placement du Quebec, Mitsubishi Tanabe Pharma, and MaRS IAF.
Yes. Cytochroma was acquired by Opko Health in January 2013.